Phaseline

Targets › CALCA

CALCA (Calcitonin [Cleaved into: Calcitonin): drug programs, companies and trials

3 programs from 3 companies in 7 trials: 7 Phase 3; Neurology; next expected readout Nov 2026.

[Calcitonin]: Peptide hormone secreted by thyroid parafollicular (C) cells that acts as a high-affinity agonist of the calcitonin receptor/CALCR that primarily couples to Gs/adenylate cyclase signaling, resulting in activation of cAMP-dependent pathways, and can additionally mobilize intracellular calcium and activate ERK signaling. Acutely lowers blood calcium levels predominantly by inhibiting osteoclast-mediated…. (UniProt, P01258)

Open in Phaseline: the race on CALCA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyGalcanezumab (LY2951742)
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Episodic Migraine; Chronic MigraineNov 2026
H. LundbeckEptinezumab
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic HeadacheMar 2027
Oslo University HospitalCGRP monoclonal antibody
CGRP receptor antagonist monoclonal antibody
CALCAPhase 3MigraineJan 2029

Conditions

Episodic Migraine (2) Migraine (2) Chronic Migraine in Children (1) Post Traumatic Headache (1) Chronic Migraine (1)

Modalities

antibody (2), protein or peptide (1)

Companies

H. Lundbeck (1) Eli Lilly (1) Oslo University Hospital (1)

Related targets

CALCB (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.